• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Struggling Mela Sciences receives de-listing notice from NASDAQ

Struggling Mela Sciences receives de-listing notice from NASDAQ

September 3, 2013 By Brian Johnson

Struggling Mela Sciences receives de-listing notice from NASDAQ

Mela Sciences (NSDQ:MELA) was warned by the NASDAQ Stock Market that it must pull its shares above $1.00 or risk being de-listed by the stock exchange.

Shares of Mela, the Irvington, N.Y.-based skin cancer diagnostic device maker, haven’t been above the $1 mark since the 1st week of July and are down some 63% in 2013. Shares of MELA closed at 65¢ per share before the holiday weekend.

Under NASDAQ rules the company will be given a 180-day grace period to pull its shares above water for 10 consecutive days before February, 2014.

The news comes on the heels of a dramatic summer for the company. In June longtime CEO Joseph Gulfo resigned his post after 9-years leading the company, and in early August the company cut 25% of its staff following disappointing Q2 results.

Mela posted losses of $7.4 million, or 17¢ per diluted share, on sales of $144.4 million during the 3 months ended June 30, 2013. That compared to Q2 2012 losses of $5.5 million, or 18¢ per share, on sales of $75.8 million. Diluted per-share earnings were on par with analysts’ expectations at 17¢.

"While we are not pleased with the commercial traction that MelaFind has gained to date, we have embarked on the restructuring announced today along with several strategic initiatives to build a successful and profitable business," interim CEO Robert Coradini said at the time.

"We are prioritizing our target list of dermatologists and their practices based on their geographic location and the proper level of support our reps and field specialists can provide," Coradini said during the quarterly conference call. "This philosophy has guided the restructuring and as of today, we have realigned our field-based organization accordingly."

Filed Under: News Well, Wall Street Beat Tagged With: MELA Sciences Inc.

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy